|
|
|
|
|
PARIS, FRANCE, 2023年9月12日 - (亞太商訊) - Ad Scientiam, a global leader in digital biomarkers, has announced a partnership with Sanofi to launch MS-DETECT, an international, multicenter, longitudinal study. MS-DETECT aims to evaluate the ability of MSCopilot(R), a medical software device, to detect early signs of disability worsening in people with multiple sclerosis (PwMS). The study will draw upon Ad Scientiam's expertise in MS and is financially supported by Sanofi.
Multiple Sclerosis (MS) is a chronic immune-mediated disease of the central nervous system that affects 2.8 million people worldwide. The disease is characterized by early inflammatory demyelination and subsequent neurodegeneration. Current clinical evaluation of PwMS relies mainly on the Expanded Disability Status Scale (EDSS), which has several limitations. To improve on these assessments, Ad Scientiam has developed MSCopilot(R), a software medical device that addresses four dimensions: ambulation/mobility, upper extremity function, cognition, and low-contrast visual acuity.
MS-DETECT's main objective is to determine MSCopilot(R)'s ability to identify subtle and early disability worsening. This will be performed by evaluating MSCopilot(R) individual and/or composite scores as compared to the Multiple Sclerosis Functional Composite (MSFC) and the EDSS.
"MS-DETECT is a pioneering large-scale longitudinal study that explores digital biomarkers for the early detection of disease progression. This study will provide important data to both clinicians and people living with MS," according to Dr. Saad Zinai, Chief Medical Officer at Ad Scientiam.
"Disability worsening in MS has been recently redefined and we now know that this progression can occur independently of relapses. With MS-DETECT, we have an opportunity to develop a digital solution to help detect and monitor the effects of smoldering disease, and evolve treatment goals for MS patients," explains Su-Peing Ng, Global Head of Medical Affairs - Specialty Care at Sanofi.
The study also aims to assess the MSCopilot(R) performance, safety, usability and satisfaction with the solution.
"Disease progression can be hard to detect in routine practice. I believe these novel digital biomarkers are key to help clinicians make appropriate treatment decisions and, ultimately, improve patients' care," said Prof. Patrick Vermersch (Lille, France), Coordinating Investigator and Chairman of the Study Steering Committee.
The MS-DETECT study will include 314 PwMS and will be conducted in the United States, Canada, Germany, Italy, Spain, Denmark and France. Several investigative sites have already been initiated in North America and Europe and first patients are expected to participate in the study during Q3 2023.
Check our LinkedIn, Facebook, Instagram pages or visit adscientiam.com
Contact Information
Saad Zinai
Chief Medical Officer
szinai@adscientiam.com
+33768008666
Matthieu Lamy
President
mlamy@adscientiam.com
+33768008666
話題 Press release summary
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network
|
|
|
|
|
|
 |
|
Latest Press Releases
MHI and Nippon Shokubai to Develop Ammonia Cracking System for NEDO's "Development of Technologies for Building a Competitive Hydrogen Supply Chain" Project
Thursday, October 30, 2025 10:14:00 PM
|
|
|
NEC and e& Sign MoU to Drive Joint Sustainability Initiatives
Thursday, October 30, 2025 9:46:00 PM
|
|
|
MHI Thermal Systems Launches Two New Models of Air-to-Water Heat Pumps Using Natural Refrigerant R290 for European Market
Thursday, October 30, 2025 9:19:00 PM
|
|
|
Decent Cybersecurity Highlights Slovakia's Tech Leadership at the EU-NZ Business Summit 
Oct 30, 2025, 21:00 HKT/SGT
|
|
|
Hitachi Energy and Blackstone Energy Transition Partners enter strategic partnership to create leading energy service provider in North America
Thursday, October 30, 2025 8:40:00 PM
|
|
|
CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Ra Humanized Monoclonal Antibody Injection MG-K10 Accepted in China
Oct 30, 2025, 20:00 HKT/SGT
|
|
|
Esperanza Unveils New Milestone in Tokenized Economy
Oct 30, 2025, 19:09 HKT/SGT
|
|
|
MHI-MS to Conduct Demonstration Testing of Vehicle Transport Robots at Nakagusuku Port in Okinawa
Thursday, October 30, 2025 4:58:00 PM
|
|
|
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
Oct 30, 2025, 16:48 HKT/SGT
|
|
|
DENSO Hosted a Press Briefing at JAPAN MOBILITY SHOW 2025
Thursday, October 30, 2025 4:29:00 PM
|
|
|
|
|
More Press release >> |
|
|
|
